Browsing Tag
Phase 2 DAHLIAS Study
1 post
Johnson & Johnson’s nipocalimab meets primary endpoint in Sjögren’s disease trial
Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren’s…